Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia.

Molecular cancer research : MCR - 5 Jul 2023

Yashar William M, Curtiss Brittany M, Coleman Daniel J, VanCampen Jake, Kong Garth, Macaraeg Jommel, Estabrook Joseph, Demir Emek, Long Nicola, Bottomly Daniel, McWeeney Shannon K, Tyner Jeffrey W, Druker Brian J, Maxson Julia E, Braun Theodore P

Abstract excerpt

Mutations in Fms-like tyrosine kinase 3 (FLT3) are common drivers in acute myeloid leukemia (AML) yet FLT3 inhibitors only provide modest clinical benefit. Prior work has shown that inhibitors of lysine-specific demethylase 1 (LSD1) enhance kinase inhibitor activity in AML. Here we show that combined LSD1 and FLT3 inhibition induces synergistic cell death in FLT3-mutant AML. Multi-omic profiling revealed that the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apoptosis
Share to fms-Like Tyrosine Kinase 3

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Histone Demethylases

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Protein Kinase Inhibitors

Share to STAT5 Transcription Factor

Source

Open in PubMed Open full text

Identifiers

PMID: 36976323
DOI: 10.1158/1541-7786.MCR-22-0745
PMCID: PMC10330306

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia.PMID 36976323Read ↗

Disruption of the MYC Super-Enhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid LeukemiaSemantic proximity Read ↗

Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cellsSemantic proximity Read ↗

Combined inhibition of JAK/STAT pathway and lysine-specific demethylase 1 as a therapeutic strategy in CSF3R/CEBPA mutant acute myeloid leukemiaSemantic proximity Read ↗

Co-targeting menin and LSD1 dismantles oncogenic programs and restores differentiation in MLL-rearranged AMLSemantic proximity Read ↗

Emerging DNA Methylome Targets in FLT3-ITD-Positive Acute Myeloid Leukemia: Combination Therapy with Clinically Approved FLT3 Inhibitors.Semantic proximity Read ↗

Multi-omics integration reveals immune hallmarks and biomarkers associated with FLT3 inhibitor sensitivity in FLT3-mutated AMLSemantic proximity Read ↗

Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AMLSemantic proximity Read ↗

LSD1 inhibition modulates transcription factor networks in myeloid malignanciesSemantic proximity Read ↗

Mutations Synergize to Alter Epigenetic and Genomic Landscape of AML.Semantic proximity Read ↗

PU.1 and MYC transcriptional network defines synergistic drug responses to KIT and LSD1 inhibition in acute myeloid leukemiaSemantic proximity Read ↗

Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemiaSemantic proximity Read ↗

A novel LSD1 inhibitor NCD38 ameliorates MDS-related leukemia with complex karyotype by attenuating leukemia programs via activating super-enhancersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.